Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Masaki Ishigai"'
Publikováno v:
IUCrData, Vol 2, Iss 9, p x171292 (2017)
In the title compound, C15H20N7O3S+·CH3O3S− (CH5132799 mesylate), two molecular entities form a salt with proton transfer from methanesulfonic acid to the aminopyrimidine moiety of CH5132799. In the crystal, methanesulfonate is retained by bifurca
Externí odkaz:
https://doaj.org/article/ca1c05c46ac14e978f3d5f6da182e843
Autor:
Akihisa Kaneko, Chihiro Endo-Tsukude, Motohiro Kato, Shino Kuramoto, Masaki Ishigai, Akinobu Hamada, Satofumi Iida
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:325-333
By using the Relative Factor (RF) method-a method that can simply assess cytochrome P450 (CYP) induction risk based on a maximum induction effect model-we evaluated the risk of CYP2C9 induction and examined its relationship with risk of CYP3A4 induct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc51075349ee3ab7655ad61350d87287
https://doi.org/10.1016/j.dmpk.2019.07.002
https://doi.org/10.1016/j.dmpk.2019.07.002
Publikováno v:
Chemical and Pharmaceutical Bulletin. 66:1035-1040
We investigated the salt cocrystals formed by tofogliflozin with sodium acetate and potassium acetate by determining the crystal structures of the salt cocrystals and characterizing the solid states. The salt cocrystal screening using the slurry meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd55d1586e2fe0a8ac57a18c0fa9fbec
https://doi.org/10.1248/cpb.c18-00483
https://doi.org/10.1248/cpb.c18-00483
Autor:
Noriyuki Takata, Koji Shiraki, Kazunori Kadota, Yuichi Tozuka, Takamitsu Ueto, Satoshi Tanida, Ryusuke Takano, Masaki Ishigai, Aya Sakon
Publikováno v:
CrystEngComm. 20:362-369
We succeeded in forming a benzoic acid cocrystal of CH5134731 by focusing on the isomorphism shown by its solvates. As a result of evaluation, the benzoic acid cocrystal showed good solubility. This crystal engineering approach made it possible to re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21aed36125dd59f00678c6286fc34748
https://doi.org/10.1039/c7ce01878a
https://doi.org/10.1039/c7ce01878a
Publikováno v:
mAbs. 9:1210-1215
The pharmacokinetics (PK) of an antibody in the brain and the spinal cord is insufficiently understood, which is an obstacle to the discovery of antibody drugs that target diseases in the central nervous system. In this study, we focused on the elimi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08829812e0b7b1f92bfc859ff0fd660f
https://doi.org/10.1080/19420862.2017.1345834
https://doi.org/10.1080/19420862.2017.1345834
Autor:
Hidetoshi Shindoh, Motohiro Kato, Nobuo Sekiguchi, Kenji Takanashi, Akihisa Kaneko, Keiichi Morita, Shunsuke Nagao, Masaki Ishigai
Publikováno v:
Xenobiotica. 47:1042-1051
1. A novel selective anaplastic lymphoma kinase (ALK) inhibitor, alectinib, has shown remarkable efficacy and safety in patients with ALK-positive non-small-cell lung cancer (NSCLC). The purpose of this study was to evaluate in vitro the potential to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::081de75058944d6147f3ca76620fffb8
https://doi.org/10.1080/00498254.2016.1261308
https://doi.org/10.1080/00498254.2016.1261308
Autor:
Yuki Iwayanagi, Tatsuhiko Tachibana, Atsuhiko Maeda, Tomoyuki Igawa, Kazuhisa Ozeki, Jun-ichi Nezu, Kenta Haraya, Masaki Ishigai
Publikováno v:
Drug Metabolism and Pharmacokinetics. 31:123-132
Previously, we have reported novel engineered antibody with pH-dependent antigen-binding (recycling antibody), and with both pH-dependent antigen-binding and increased FcRn-binding at neutral pH (sweeping antibody). The purpose of this study is to pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf5fbe874e2b0286c0ce2971b9e48727
https://doi.org/10.1016/j.dmpk.2015.12.007
https://doi.org/10.1016/j.dmpk.2015.12.007
Autor:
Chiyomi Kubo, Akira Takeiri, Futa Mimoto, Naoaki Murao, Shunsuke Ito, Shotaro Takata, Atsuhiko Maeda, Masaki Ishigai, Kumiko Muraoka, Yuki Iwayanagi, Ayako Takahashi, Nobuo Sekiguchi, Shuichi Chiba, Mariko Yano, Tetsuya Wakabayashi
Publikováno v:
mAbs. 10(8)
Immunogenicity is a key factor capable of influencing the efficacy and safety of therapeutic antibodies. A recently developed method called MHC-associated peptide proteomics (MAPPs) uses liquid chromatography/mass spectrometry to identify the peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58007c5ed97d97a87fc224910c5653f8
https://pubmed.ncbi.nlm.nih.gov/30199322
https://pubmed.ncbi.nlm.nih.gov/30199322
Publikováno v:
Drug Metabolism and Pharmacokinetics. 34:S42-S43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc35d5eb440d618514fc9ae9e92cfbfd
https://doi.org/10.1016/j.dmpk.2018.09.155
https://doi.org/10.1016/j.dmpk.2018.09.155
Publikováno v:
IUCrData, Vol 2, Iss 9, p x171292 (2017)
In the title compound, C15H20N7O3S+·CH3O3S−(CH5132799 mesylate), two molecular entities form a salt with proton transfer from methanesulfonic acid to the aminopyrimidine moiety of CH5132799. In the crystal, methanesulfonate is retained by bifurcat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea6e66dc447b45297963685549c072c7
http://scripts.iucr.org/cgi-bin/paper?S2414314617012925
http://scripts.iucr.org/cgi-bin/paper?S2414314617012925